Four-year follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder / Jeffrey R. WOZNIAK in Journal of Neurodevelopmental Disorders, 12 (2020)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 12 (2020) Titre : Four-year follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder Type de document : texte imprimé Auteurs : Jeffrey R. WOZNIAK, Auteur ; Birgit A. FINK, Auteur ; Anita J. FUGLESTAD, Auteur ; Judith K. ECKERLE, Auteur ; Christopher J. BOYS, Auteur ; Kristin E. SANDNESS, Auteur ; Joshua P. RADKE, Auteur ; Neely C. MILLER, Auteur ; Christopher LINDGREN, Auteur ; Ann M. BREARLEY, Auteur ; Steven H. ZEISEL, Auteur ; Michael K. GEORGIEFF, Auteur Langues : Anglais (eng) Mots-clés : Child, Preschool  Choline/therapeutic use  Cognition/drug effects  Double-Blind Method  Female  Fetal Alcohol Spectrum Disorders/drug therapy  Follow-Up Studies  Humans  Intelligence/drug effects  Male  Memory, Short-Term/drug effects  Nootropic Agents/therapeutic use  Pregnancy  Prenatal Exposure Delayed Effects/drug therapy  Choline  Cognition  Fetal alcohol spectrum disorders  Longitudinal studies  Randomized controlled trials Index. décimale : PER Périodiques Résumé : BACKGROUND: Despite the high prevalence of fetal alcohol spectrum disorder (FASD), there are few interventions targeting its core neurocognitive and behavioral deficits. FASD is often conceptualized as static and permanent, but interventions that capitalize on brain plasticity and critical developmental windows are emerging. We present a long-term follow-up study evaluating the neurodevelopmental effects of choline supplementation in children with FASD 4 years after an initial efficacy trial. METHODS: The initial study was a randomized, double-blind, placebo-controlled trial of choline vs. placebo in 2-5-year-olds with FASD. Participants include 31 children (16 placebo; 15 choline) seen 4 years after trial completion. The mean age at follow-up was 8.6 years. Diagnoses were 12.9% fetal alcohol syndrome (FAS), 41.9% partial FAS, and 45.1% alcohol-related neurodevelopmental disorder. The follow-up included measures of intelligence, memory, executive functioning, and behavior. RESULTS: Children who received choline had higher non-verbal intelligence, higher visual-spatial skill, higher working memory ability, better verbal memory, and fewer behavioral symptoms of attention deficit hyperactivity disorder than the placebo group. No differences were seen for verbal intelligence, visual memory, or other executive functions. CONCLUSIONS: These data support choline as a potential neurodevelopmental intervention for FASD and highlight the need for long-term follow-up to capture treatment effects on neurodevelopmental trajectories. TRIAL REGISTRATION: ClinicalTrials.Gov #NCT01149538; Registered: June 23, 2010; first enrollment July 2, 2010. En ligne : https://dx.doi.org/10.1186/s11689-020-09312-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573 [article] Four-year follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder [texte imprimé] / Jeffrey R. WOZNIAK, Auteur ; Birgit A. FINK, Auteur ; Anita J. FUGLESTAD, Auteur ; Judith K. ECKERLE, Auteur ; Christopher J. BOYS, Auteur ; Kristin E. SANDNESS, Auteur ; Joshua P. RADKE, Auteur ; Neely C. MILLER, Auteur ; Christopher LINDGREN, Auteur ; Ann M. BREARLEY, Auteur ; Steven H. ZEISEL, Auteur ; Michael K. GEORGIEFF, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 12 (2020) Mots-clés : Child, Preschool  Choline/therapeutic use  Cognition/drug effects  Double-Blind Method  Female  Fetal Alcohol Spectrum Disorders/drug therapy  Follow-Up Studies  Humans  Intelligence/drug effects  Male  Memory, Short-Term/drug effects  Nootropic Agents/therapeutic use  Pregnancy  Prenatal Exposure Delayed Effects/drug therapy  Choline  Cognition  Fetal alcohol spectrum disorders  Longitudinal studies  Randomized controlled trials Index. décimale : PER Périodiques Résumé : BACKGROUND: Despite the high prevalence of fetal alcohol spectrum disorder (FASD), there are few interventions targeting its core neurocognitive and behavioral deficits. FASD is often conceptualized as static and permanent, but interventions that capitalize on brain plasticity and critical developmental windows are emerging. We present a long-term follow-up study evaluating the neurodevelopmental effects of choline supplementation in children with FASD 4 years after an initial efficacy trial. METHODS: The initial study was a randomized, double-blind, placebo-controlled trial of choline vs. placebo in 2-5-year-olds with FASD. Participants include 31 children (16 placebo; 15 choline) seen 4 years after trial completion. The mean age at follow-up was 8.6 years. Diagnoses were 12.9% fetal alcohol syndrome (FAS), 41.9% partial FAS, and 45.1% alcohol-related neurodevelopmental disorder. The follow-up included measures of intelligence, memory, executive functioning, and behavior. RESULTS: Children who received choline had higher non-verbal intelligence, higher visual-spatial skill, higher working memory ability, better verbal memory, and fewer behavioral symptoms of attention deficit hyperactivity disorder than the placebo group. No differences were seen for verbal intelligence, visual memory, or other executive functions. CONCLUSIONS: These data support choline as a potential neurodevelopmental intervention for FASD and highlight the need for long-term follow-up to capture treatment effects on neurodevelopmental trajectories. TRIAL REGISTRATION: ClinicalTrials.Gov #NCT01149538; Registered: June 23, 2010; first enrollment July 2, 2010. En ligne : https://dx.doi.org/10.1186/s11689-020-09312-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573

Neurobehavioral outcomes of neonatal asymptomatic congenital cytomegalovirus infection at 12-months / Sally M. STOYELL in Journal of Neurodevelopmental Disorders, 16 (2024)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 16 (2024) Titre : Neurobehavioral outcomes of neonatal asymptomatic congenital cytomegalovirus infection at 12-months Type de document : texte imprimé Auteurs : Sally M. STOYELL, Auteur ; Jed T. ELISON, Auteur ; Emily GRAUPMANN, Auteur ; Neely C. MILLER, Auteur ; Jessica EMERICK, Auteur ; Elizabeth RAMEY, Auteur ; Kristen SANDNESS, Auteur ; Mark R. SCHLEISS, Auteur ; Erin A. OSTERHOLM, Auteur Langues : Anglais (eng) Mots-clés : Infant, Newborn  Infant  Humans  Child, Preschool  Cytomegalovirus  Longitudinal Studies  Cytomegalovirus Infections/complications/epidemiology/diagnosis  Neonatal Screening/methods  Brain  Congenital CMV infection  Intellectual disability  TORCH infections Index. décimale : PER Périodiques Résumé : BACKGROUND: Congenital cytomegalovirus (cCMV) is the most common congenital viral infection in the United States. Symptomatic infections can cause severe hearing loss and neurological disability, although ~ 90% of cCMV infections are asymptomatic at birth. Despite its prevalence, the long-term neurobehavioral risks of asymptomatic cCMV infections are not fully understood. The objective of this work was to evaluate for potential long-term neurobehavioral sequelae in infants with asymptomatic cCMV. METHODS: Infants with cCMV were identified from a universal newborn cCMV screening study in a metropolitan area in the midwestern United States. Asymptomatic infants with cCMV were enrolled in a longitudinal neurodevelopmental study (N = 29). Age- and sex-matched healthy control infants (N = 193) were identified from the Baby Connectome Project (BCP), a longitudinal study of brain and behavioral development. The BCP sample supplemented an additional group of healthy control infants (N = 30), recruited from the same participant registry as the BCP specifically for comparison with infants with asymptomatic cCMV. Neurobehavioral assessments and parent questionnaires, including the Mullen Scales of Early Learning, the Repetitive Behavior Scales for Early Childhood (RBS-EC), and the Infant Toddler Social Emotional Assessment (ITSEA) were administered at 12 months of age. Neurobehavioral scores were compared between infants with asymptomatic cCMV and all identified healthy control infants. RESULTS: Infants with asymptomatic cCMV performed equivalently compared to healthy control infants on the neurobehavioral measures tested at 12 months of age. CONCLUSIONS: These results indicate that at 12 months of age, infants with asymptomatic cCMV are not statistically different from controls in a number of neurobehavioral domains. Although follow-up is ongoing, these observations provide reassurance about neurobehavioral outcomes for infants with asymptomatic cCMV and inform the ongoing discussion around universal screening. Additional follow-up will be necessary to understand the longer-term outcomes of these children. En ligne : https://dx.doi.org/10.1186/s11689-024-09533-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=575 [article] Neurobehavioral outcomes of neonatal asymptomatic congenital cytomegalovirus infection at 12-months [texte imprimé] / Sally M. STOYELL, Auteur ; Jed T. ELISON, Auteur ; Emily GRAUPMANN, Auteur ; Neely C. MILLER, Auteur ; Jessica EMERICK, Auteur ; Elizabeth RAMEY, Auteur ; Kristen SANDNESS, Auteur ; Mark R. SCHLEISS, Auteur ; Erin A. OSTERHOLM, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 16 (2024) Mots-clés : Infant, Newborn  Infant  Humans  Child, Preschool  Cytomegalovirus  Longitudinal Studies  Cytomegalovirus Infections/complications/epidemiology/diagnosis  Neonatal Screening/methods  Brain  Congenital CMV infection  Intellectual disability  TORCH infections Index. décimale : PER Périodiques Résumé : BACKGROUND: Congenital cytomegalovirus (cCMV) is the most common congenital viral infection in the United States. Symptomatic infections can cause severe hearing loss and neurological disability, although ~ 90% of cCMV infections are asymptomatic at birth. Despite its prevalence, the long-term neurobehavioral risks of asymptomatic cCMV infections are not fully understood. The objective of this work was to evaluate for potential long-term neurobehavioral sequelae in infants with asymptomatic cCMV. METHODS: Infants with cCMV were identified from a universal newborn cCMV screening study in a metropolitan area in the midwestern United States. Asymptomatic infants with cCMV were enrolled in a longitudinal neurodevelopmental study (N = 29). Age- and sex-matched healthy control infants (N = 193) were identified from the Baby Connectome Project (BCP), a longitudinal study of brain and behavioral development. The BCP sample supplemented an additional group of healthy control infants (N = 30), recruited from the same participant registry as the BCP specifically for comparison with infants with asymptomatic cCMV. Neurobehavioral assessments and parent questionnaires, including the Mullen Scales of Early Learning, the Repetitive Behavior Scales for Early Childhood (RBS-EC), and the Infant Toddler Social Emotional Assessment (ITSEA) were administered at 12 months of age. Neurobehavioral scores were compared between infants with asymptomatic cCMV and all identified healthy control infants. RESULTS: Infants with asymptomatic cCMV performed equivalently compared to healthy control infants on the neurobehavioral measures tested at 12 months of age. CONCLUSIONS: These results indicate that at 12 months of age, infants with asymptomatic cCMV are not statistically different from controls in a number of neurobehavioral domains. Although follow-up is ongoing, these observations provide reassurance about neurobehavioral outcomes for infants with asymptomatic cCMV and inform the ongoing discussion around universal screening. Additional follow-up will be necessary to understand the longer-term outcomes of these children. En ligne : https://dx.doi.org/10.1186/s11689-024-09533-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=575

---

1 (1 - 2 / 2) Par page : 25 50 100 200